These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9691110)

  • 1. Treatment of Crohn's disease at the turn of the century.
    Bickston SJ; Cominelli F
    N Engl J Med; 1998 Aug; 339(6):401-2. PubMed ID: 9691110
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
    Bauditz J; Lochs H; Schreiber S
    N Engl J Med; 1998 Jan; 338(5):334. PubMed ID: 9446035
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug therapy of Crohn disease].
    Niemelä S
    Duodecim; 2001; 117(8):807-14. PubMed ID: 12116446
    [No Abstract]   [Full Text] [Related]  

  • 7. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
    Rutgeerts P
    Gut; 1999 Jul; 45(1):13-4. PubMed ID: 10498451
    [No Abstract]   [Full Text] [Related]  

  • 8. [Drug therapy of inflammatory bowel diseases].
    Silvennoinen J; Niemelä S
    Duodecim; 1999; 115(20):2233-8. PubMed ID: 11973927
    [No Abstract]   [Full Text] [Related]  

  • 9. Algorithm for the treatment of Crohn's disease: incorporation of emerging therapies.
    Souney PF
    Am J Gastroenterol; 2000 Sep; 95(9):2381-3. PubMed ID: 11007248
    [No Abstract]   [Full Text] [Related]  

  • 10. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New therapeutic modalities in Crohn's disease].
    Rachmilewitz D
    Harefuah; 1999 Jun; 136(12):943-5. PubMed ID: 10955155
    [No Abstract]   [Full Text] [Related]  

  • 12. [Paradigmatic shift in drug treatment of Crohn disease].
    Munck LK
    Ugeskr Laeger; 2005 Aug; 167(33):3013. PubMed ID: 16109239
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison of budesonide and mesalamine for active Crohn's disease.
    Lowry PW; Sandborn WJ
    Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523
    [No Abstract]   [Full Text] [Related]  

  • 14. Budesonide modified-release capsules.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
    MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
    Rutgeerts P
    Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
    Bischoff A
    MMW Fortschr Med; 2010 Jan; 152(1-2):20. PubMed ID: 20302159
    [No Abstract]   [Full Text] [Related]  

  • 18. [Maintaining a remission].
    Fleig WE;
    Z Gastroenterol; 2003 Jan; 41(1):36-42. PubMed ID: 12541172
    [No Abstract]   [Full Text] [Related]  

  • 19. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
    Feagan BG
    Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.